WASHINGTON, July 17, 2013 /PRNewswire-USNewswire/ -- The Chinese government is taking a hard line against pharmaceutical companies that violate anti-bribery laws, as seen by the recent actions taken against multinational firms. But this tough enforcement — in what is projected to be the second largest pharmaceutical market in the world — is not limited to only the drug industry. The Food and Drug Law Institute's China-US Updates in Food and Drug Law conference being held in Beijing on October 15-16 will address recent enforcement actions against pharmaceutical, medical device and food companies both in China and the US, focusing on the Foreign Corrupt Practices Act (FCPA), anti-bribery actions and stricter penalties. Learn more.
Contact: Erin Jones, VP, Marketing, email@example.com, 202-222-0899
SOURCE Food and Drug Law Institute